The Cold Open
Semax is marketed in the US as a focus-enhancing nootropic you spray up your nose before deep work. In Russia, where it's actually approved as a medicine, the use case is different. Doctors prescribe it to stroke patients. That mismatch between "cognitive enhancer" and "neuroprotective rescue drug" is the story this month.
Peptide of the Month: Semax
What it is. Semax is a seven-amino-acid synthetic peptide built from a piece of adrenocorticotropic hormone (ACTH), with a short protective tail added to keep it from breaking down in the bloodstream. It was developed in Russia in the 1980s and 90s, delivered intranasally so it can reach the brain without being destroyed. Think of it as a short, weaponized fragment of one of your own signaling hormones, redesigned to target neurons rather than the adrenal system the parent hormone is famous for.
What it's supposedly for. Two very different uses. In Russian medicine, it's approved as an adjunct therapy for acute ischemic stroke, delivered at a higher 1% concentration during the critical post-stroke window. In biohacker circles, it's marketed as a long-term nootropic at a weaker 0.1% concentration for focus, memory, and mental fatigue.
The evidence as of today. The stroke evidence is the strongest part of the file. A 2018 trial in 110 stroke patients found those receiving Semax alongside standard rehab had higher blood levels of BDNF (a key neurotrophic factor), faster motor recovery, and better functional outcomes. An earlier 1997 trial established safety and dosing. A 2018 fMRI study in healthy adults showed intranasal Semax acutely shifts activity in the Default Mode Network, confirming it actually does something to the brain on demand.
One thing to know: BDNF. Semax's main established mechanism is rapidly boosting Brain-Derived Neurotrophic Factor. BDNF is a protein that supports neuronal survival and plasticity. That's a real effect, measured in blood, and it's what gives Semax a genuinely interesting neuroscience profile.
The stroke trials are solid. The nootropic trials are mostly Russian and mostly old.
The catch. Not FDA-approved in the US. Every vial sold here comes from a research-chemical vendor. The bigger issue, though, is that the nootropic marketing borrows from the stroke research. Neuroprotection during an acute ischemic event is not the same thing as getting smarter during a coding session. The BDNF-boost data is real. The "Semax improves my focus at work" data is mostly anecdotal and heavily Russian.
Myth Check: "Semax is a proven nootropic"
The nootropic pitch presents Semax as a well-studied, clinically validated cognitive enhancer. The Russian approval is often cited as if it settles the question.
It doesn't. Russia approved Semax for acute neurological events (stroke, optic nerve damage), not for daily nootropic use in healthy adults. The healthy-subject studies that do exist are mostly small, mostly Russian, and mostly from the 1990s. The one modern fMRI study confirms Semax acutely modulates a brain network. That's a mechanism, not a benefit. No large, modern, Western-indexed trial has demonstrated that daily Semax improves real-world focus, memory, or work output in healthy adults.
The rule: If the evidence base for a peptide is "proven for stroke" and the marketing is "proven for focus," you're looking at a bridge that hasn't been built yet.
Not medical advice. Most peptides discussed in this newsletter are investigational or research chemicals. Talk to a clinician before starting anything.